ArticleCancer management and research2026
Development and Validation of a Nomogram Integrating Body Composition and Inflammatory Markers to Predict Concurrent Chemoradiotherapy Response in Locally Advanced Cervical Cancer.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To develop and validate a nomogram integrating body composition and systemic inflammatory markers for predicting sensitivity to concurrent chemoradiotherapy (CCRT) in patients with locally advanced cervical cancer (LACC). Patients and Methods: This single-center retrospective study included 215 patients with FIGO 2018 stage IIB-IVA LACC who received first-line CCRT between September 2020 and September 2024. Patients were randomly assigned to a training set (n=150) and a test set (n=65). Treatment response was assessed approximately 8 weeks after radiotherapy according to RECIST version 1.1. Patients with complete or partial response were classified as CCRT-sensitive, whereas those with stable or progressive disease were classified as CCRT-resistant. Multivariable logistic regression was used to identify independent predictors and construct a nomogram. Model performance was evaluated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA), and was compared with clinical-only, systemic inflammatory, and body composition models. Results: Tumor size, platelet-to-lymphocyte ratio, prognostic nutritional index, skeletal muscle index, and visceral adipose index were identified as independent predictors of CCRT sensitivity and were incorporated into the nomogram. The model showed good discrimination, with an area under the ROC curve of 0.796 (95% CI, 0.714-0.878) in the training set and 0.751 (95% CI, 0.618-0.884) in the test set. At the optimal cutoff probability of 0.66, sensitivity and specificity were 75.7% and 72.1% in the training set, and 79.1% and 59.1% in the test set, respectively. Calibration curves showed good agreement, and DCA indicated favorable clinical utility. The nomogram outperformed the three single-domain models. Conclusion: We developed and internally validated a non-invasive nomogram integrating tumor size, systemic inflammatory markers, and CT-based body composition parameters to predict CCRT sensitivity in LACC. This model may assist in early risk stratification and individualized treatment planning, although external validation in larger multicenter cohorts is still needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.